Oragenics (OGEN) Retained Earnings (2010 - 2026)
Oragenics' (OGEN) quarterly Retained Earnings came in at $235.0 million in Q1 2026, up 207.31% YoY from $76.5 million in Q1 2025, and up 203.7% on a QoQ basis from -$226.6 million in Q4 2025.
Oragenics (OGEN) Retained Earnings (2010 - 2026) Analysis & Trends
Oragenics (OGEN) has 17 years of Retained Earnings data on file, last reported at $235.0 million in Q1 2026.
- Quarterly Retained Earnings rose 207.31% year-over-year to $235.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $235.0 million (up 207.31% YoY) and the FY2025 annual result came in at -$226.6 million, down 204.64% from the prior year.
- Retained Earnings climbed to $235.0 million in Q1 2026, from -$226.6 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $235.0 million in Q1 2026 to a low of -$226.6 million in Q4 2025.
- A 5-year average of -$11.9 million and a median of -$183.0 million in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings soared 221.33% — and 2024, when it tumbled 205.89%.
- Tracing OGEN's Retained Earnings over 5 years: stood at -$185.6 million in 2022, then retreated by 11.13% to -$206.2 million in 2023, then jumped by 205.02% to $216.6 million in 2024, then plunged by 204.64% to -$226.6 million in 2025, then soared by 203.7% to $235.0 million in 2026.
- The last three Retained Earnings figures came in at $235.0 million (Q1 2026), -$226.6 million (Q4 2025), and -$224.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | Oragenics | 2.38 Mn | 2.38 Mn | - | 235.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 235.02 Mn |
| Mar 31, 2026 | 235.01 Mn |
| Dec 31, 2025 | -226.63 Mn |
| Sep 30, 2025 | -224.00 Mn |
| Jun 30, 2025 | -221.28 Mn |
| Mar 31, 2025 | -219.00 Mn |
| Dec 31, 2024 | 216.57 Mn |
| Sep 30, 2024 | 214.91 Mn |
| Jun 30, 2024 | 210.70 Mn |
| Mar 31, 2024 | -208.67 Mn |
| Dec 31, 2023 | -206.22 Mn |
| Sep 30, 2023 | 198.37 Mn |
| Jun 30, 2023 | -191.46 Mn |
| Mar 31, 2023 | 197.06 Mn |
| Dec 31, 2022 | -185.56 Mn |
| Sep 30, 2022 | -183.00 Mn |
| Jun 30, 2022 | 195.36 Mn |
| Mar 31, 2022 | 195.08 Mn |
| Dec 31, 2021 | 195.10 Mn |
| Sep 30, 2021 | 194.75 Mn |